Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors

Provided By Globe Newswire

Last update: Sep 7, 2022

- Successful biopharma entrepreneur with 25 years of experience growing leading healthcare firms -

LONDON, Ontario, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022. Dr. Mahony is Entrepreneur-in-Residence at Evotec and is also responsible for managing Evotec’s equity investment portfolio.